Hasan Şenol Çoşkun

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Markus Moehler, Mikhail Dvorkin, Narikazu Boku et al. · Journal of Clinical Oncology · 2020 · 223 citations · Full text

Medicine, Oncology, Pharmacology +15

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16